Vectura Group PLC’s (VEC) “Hold” Rating Reaffirmed at Peel Hunt
Several other equities analysts also recently commented on VEC. Panmure Gordon reissued a buy rating and set a GBX 150 ($1.97) target price on shares of Vectura Group PLC in a research report on Thursday. Shore Capital reissued a buy rating on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Numis Securities Ltd lowered their target price on shares of Vectura Group PLC from GBX 205 ($2.70) to GBX 170 ($2.24) and set a buy rating on the stock in a research report on Thursday. J P Morgan Chase & Co lowered their target price on shares of Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an overweight rating on the stock in a research report on Thursday, September 21st. Finally, Citigroup Inc. lowered their target price on shares of Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating on the stock in a research report on Monday, September 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of GBX 189.67 ($2.49).
Vectura Group PLC (LON:VEC) traded down GBX 0.15 ($0.00) during trading on Thursday, reaching GBX 90.55 ($1.19). 2,724,522 shares of the company’s stock traded hands, compared to its average volume of 1,560,000. Vectura Group PLC has a 52-week low of GBX 86.50 ($1.14) and a 52-week high of GBX 166.97 ($2.20).
In other news, insider Bruno Angelici bought 70,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were acquired at an average cost of GBX 99 ($1.30) per share, with a total value of £69,300 ($91,148.23). Also, insider Andrew Derodra bought 82,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were purchased at an average cost of GBX 90 ($1.18) per share, for a total transaction of £73,800 ($97,066.95). Over the last ninety days, insiders bought 152,456 shares of company stock worth $14,354,880.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.